The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities
Clinical Pharmacology in Drug Development · 2026
DOI: 10.1002/cpdd.70001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Nila Ganamurali und 1 weiteren Autor:innen. Beteiligte Einrichtung: Helix Research Lab, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chenna…. Hauptthemen laut MEDLINE: Obesity, Glucagon-Like Peptide-1 Receptor Agonists, Anti-Obesity Agents, Receptors, Gastrointestinal Hormone. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Obesity has emerged as a global health crisis requiring innovative therapeutic strategies beyond conventional approaches. While glucagon‐like peptide‐1 (GLP‐1) and dual GIP/GLP‐1 receptor agonists have redefined pharmacological management, their limitations necessitate further innovation. Retatrutide (LY3437943), a novel triple agonist targeting GLP‐1, glucose‐dependent insulinotropic polypeptide (GIP), and glucagon receptors, represents a transformative advance in obesity pharmacotherapy. Phase 2 trials report unprecedented weight reductions, comparable to bariatric surgery, with additional benefits for metabolic comorbidities such as NASH and cardiovascular disease. Retatrutide exemplifies rational multi‐agonist peptide engineering and signals a paradigm shift in systems pharmacology. This perspective underscores the urgent need for scientific engagement, equity considerations, and policy preparedness, positioning retatrutide as a watershed in obesity treatment and a blueprint for future poly‐agonist therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Helix Research Lab, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, Tamil Nadu, India.
Zitieren
APA
Ganamurali, N., & Sabarathinam, S. (2026). The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70001
Vancouver
Ganamurali N, Sabarathinam S. The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70001
BibTeX
@article{Ganamurali2026,
author = {Ganamurali, Nila and Sabarathinam, Sarvesh},
title = {The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
doi = {10.1002/cpdd.70001}
}
EUVIMED